Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Colorcon
Johnson and Johnson
McKesson
Baxter

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for PF-03715455


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug PF-03715455?

PF-03715455 is an investigational drug.

There have been 4 clinical trials for PF-03715455. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are nineteen US patents protecting this investigational drug and two hundred and ninety international patents.

Recent Clinical Trials for PF-03715455
TitleSponsorPhase
An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary DiseasePfizerPhase 2
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled AsthmaPfizerPhase 2
Single Dose Lipopolysaccharide (LPS) Study In Healthy VolunteersPfizerPhase 1

See all PF-03715455 clinical trials

Clinical Trial Summary for PF-03715455

Top disease conditions for PF-03715455
Top clinical trial sponsors for PF-03715455

See all PF-03715455 clinical trials

US Patents for PF-03715455

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-03715455 ⤷  Try it Free Autotaxin inhibitors Novartis AG (Basel, CH) ⤷  Try it Free
PF-03715455 ⤷  Try it Free Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Try it Free
PF-03715455 ⤷  Try it Free Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try it Free
PF-03715455 ⤷  Try it Free P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (Cambridge, MA) ⤷  Try it Free
PF-03715455 ⤷  Try it Free P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics. Inc. (Cambridge, MA) ⤷  Try it Free
PF-03715455 ⤷  Try it Free Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Try it Free
PF-03715455 ⤷  Try it Free Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors Pfizer Inc. (New York, NY) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-03715455

Drugname Country Document Number Estimated Expiration Related US Patent
PF-03715455 Australia AU2014291711 2033-07-18 ⤷  Try it Free
PF-03715455 Brazil BR112016000779 2033-07-18 ⤷  Try it Free
PF-03715455 Canada CA2918284 2033-07-18 ⤷  Try it Free
PF-03715455 Chile CL2016000117 2033-07-18 ⤷  Try it Free
PF-03715455 China CN105555783 2033-07-18 ⤷  Try it Free
PF-03715455 Costa Rica CR20160033 2033-07-18 ⤷  Try it Free
PF-03715455 Cuba CU20160007 2033-07-18 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Colorcon
Johnson and Johnson
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.